🔎 Trials Near Me

Utama › Kanser Kelenjar Liur › New York

Kajian klinikal Kanser Kelenjar Liur di New York

5 kajian untuk Kanser Kelenjar Liur sedang mencari peserta di lokasi di New York.

Bandar di New York

Teks kajian rasmi (Bahasa Inggeris)

Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers

  • Memorial Sloan Kettering Commack, Commack
  • Memorial Sloan Kettering Westchester, Harrison
  • Mount Sinai Hospital, New York
  • dan 2 lagi
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 17 Ogo 2026 · NCT05408845

A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors

  • Memorial Sloan Kettering Cancer Center, New York
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 10 Jul 2026 · NCT06695845

Integrated Cancer Repository for Cancer Research

  • C.R. Wood Cancer Center, Glens Falls Hospital, Glens Falls
  • Faxton St. Luke's Healthcare, Mohawk Valley, Utica
Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
Umur 19 hingga 110 · Semua jantina · Dikemas kini 29 Jun 2026 · NCT02012699

Post-op T-DM1 in HER-2+ Salivary Gland Carcinomas

  • Memorial Sloan Kettering Commack, Commack
  • Memorial Sloan Kettering Westchester, Harrison
  • David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York
  • dan 2 lagi
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 13 Apr 2026 · NCT04620187

VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma

  • Weill Cornell Medicine, Cornell University (site 126), New York
Mengambil pesertaFasa 1/2
Umur 18 hingga 80 · Semua jantina · Dikemas kini 11 Dis 2025 · NCT03556228

Daripada ClinicalTrials.gov, data diperoleh pada 6 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.